We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integer Holdings (ITGR) Q3 Earnings Beat Estimates, Down Y/Y
Read MoreHide Full Article
Integer Holdings Corporation (ITGR - Free Report) reported third-quarter 2020 adjusted earnings per share (EPS) of 50 cents, which outpaced the Zacks Consensus Estimate of 32 cents by 56.3%. However, the bottom line plunged 58.3% on a year-over-year basis.
Revenues declined 22.3% year over year to $235.9 million on a reported basis. Nonetheless, the top line beat the Zacks Consensus Estimate by 2.7%.
Segmental Analysis
Integer Holdings operates through two segments — Medical Sales and Non-Medical Sales.
Medical Sales
At the segment, reported revenues were $227.7 million, down 21.3% year over year. Revenues declined 22.3% from the prior-year quarter on an organic basis.
Medical Sales has three sub-segments — Advanced Surgical, Orthopedics and Portable Medical (AS&O); Cardio & Vascular; and Cardiac & Neuromodulation.
Advanced Surgical, Orthopedics and Portable Medical
Integer Holdings’ Advanced Surgical, Orthopedics & Portable Medical segment has been divested to Viant. Consequently, revenues at the segment comprise net sales from acquirer Viant under supply agreements associated with the divestiture.
Revenues amounted to $30.2 million, down 12% year over year and 12.2% on an organic basis. Per management, the downside was due to the impact of the COVID-19 pandemic and a blend of customers’ responses.
Integer Holdings Corporation Price, Consensus and EPS Surprise
Revenues at the segment totaled $124.6 million, down 16.1% from the prior-year quarter and 18% organically. Per management, this was owing to the impact of the pandemic and customers’ responses throughout nearly all Cardio & Vascular markets.
Cardiac & Neuromodulation
Revenues at this segment totaled $72.9 million, declining 31.6% on both year-over-year and organic basis. This was due to Nuvectra bankruptcy ($3 million headwind) and decline in CRM and Neuromodulation (corresponding to the impact of the pandemic and a blend of customers’ responses).
Non-Medical Sales
Reported revenues at the segment totaled $8.3 million, down 41.7% on both year-over-year and organic basis.
Margin Analysis
Integer Holdings generated a gross profit of $57.9 million in the third quarter, down 37.9% year over year. As a percentage of revenues, gross margin in the reported quarter contracted 620 basis points (bps) to 24.6%. Selling, general and administrative expenses (SG&A) were $3.6 million, down 89% year over year.
Research, development and engineering costs were $11.9 million in the quarter, up 1.4% year over year.
Total operating income amounted to $39.8 million, which declined 14.5% year over year.
Operating margin in the quarter under review was 16.9%, up 160 bps year over year.
Q4 Guidance
The company projects sales to be $20-$35 million higher than that of third quarter. Adjusted operating income margin is expected to be 200-300 bps higher than the third quarter.
Summing Up
Integer Holdings exited the third quarter on a strong note, wherein both earnings and revenues beat their respective Zacks Consensus Estimates. However, the company witnessed weak performance across its segments in the quarter under review. Also, contraction in gross margin is a dampener.
Nonetheless, strong demand across key areas like structural heart is a tailwind. Further, higher demand for ventilator and patient monitoring components fuel optimism. Also, expansion in operating margin is a positive.
Zacks Rank
Currently, Integer Holdings carries a Zacks Rank #3 (Hold).
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks in the broader medical space that have already announced their quarterly results are Thermo Fisher Scientific Inc. (TMO - Free Report) , Align Technology, Inc. (ALGN - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While both Thermo Fisher and AngioDynamics carry aZacks Rank of 2 (Buy), Align Technology sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
AngioDynamics reported first-quarter fiscal 2021 adjusted earnings per share (EPS) of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
Have You Seen Zacks’ 2020 Election Stock Report?
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.
The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Image: Bigstock
Integer Holdings (ITGR) Q3 Earnings Beat Estimates, Down Y/Y
Integer Holdings Corporation (ITGR - Free Report) reported third-quarter 2020 adjusted earnings per share (EPS) of 50 cents, which outpaced the Zacks Consensus Estimate of 32 cents by 56.3%. However, the bottom line plunged 58.3% on a year-over-year basis.
Revenues declined 22.3% year over year to $235.9 million on a reported basis. Nonetheless, the top line beat the Zacks Consensus Estimate by 2.7%.
Segmental Analysis
Integer Holdings operates through two segments — Medical Sales and Non-Medical Sales.
Medical Sales
At the segment, reported revenues were $227.7 million, down 21.3% year over year. Revenues declined 22.3% from the prior-year quarter on an organic basis.
Medical Sales has three sub-segments — Advanced Surgical, Orthopedics and Portable Medical (AS&O); Cardio & Vascular; and Cardiac & Neuromodulation.
Advanced Surgical, Orthopedics and Portable Medical
Integer Holdings’ Advanced Surgical, Orthopedics & Portable Medical segment has been divested to Viant. Consequently, revenues at the segment comprise net sales from acquirer Viant under supply agreements associated with the divestiture.
Revenues amounted to $30.2 million, down 12% year over year and 12.2% on an organic basis. Per management, the downside was due to the impact of the COVID-19 pandemic and a blend of customers’ responses.
Integer Holdings Corporation Price, Consensus and EPS Surprise
Integer Holdings Corporation price-consensus-eps-surprise-chart | Integer Holdings Corporation Quote
Cardio & Vascular
Revenues at the segment totaled $124.6 million, down 16.1% from the prior-year quarter and 18% organically. Per management, this was owing to the impact of the pandemic and customers’ responses throughout nearly all Cardio & Vascular markets.
Cardiac & Neuromodulation
Revenues at this segment totaled $72.9 million, declining 31.6% on both year-over-year and organic basis. This was due to Nuvectra bankruptcy ($3 million headwind) and decline in CRM and Neuromodulation (corresponding to the impact of the pandemic and a blend of customers’ responses).
Non-Medical Sales
Reported revenues at the segment totaled $8.3 million, down 41.7% on both year-over-year and organic basis.
Margin Analysis
Integer Holdings generated a gross profit of $57.9 million in the third quarter, down 37.9% year over year. As a percentage of revenues, gross margin in the reported quarter contracted 620 basis points (bps) to 24.6%.
Selling, general and administrative expenses (SG&A) were $3.6 million, down 89% year over year.
Research, development and engineering costs were $11.9 million in the quarter, up 1.4% year over year.
Total operating income amounted to $39.8 million, which declined 14.5% year over year.
Operating margin in the quarter under review was 16.9%, up 160 bps year over year.
Q4 Guidance
The company projects sales to be $20-$35 million higher than that of third quarter. Adjusted operating income margin is expected to be 200-300 bps higher than the third quarter.
Summing Up
Integer Holdings exited the third quarter on a strong note, wherein both earnings and revenues beat their respective Zacks Consensus Estimates. However, the company witnessed weak performance across its segments in the quarter under review. Also, contraction in gross margin is a dampener.
Nonetheless, strong demand across key areas like structural heart is a tailwind. Further, higher demand for ventilator and patient monitoring components fuel optimism. Also, expansion in operating margin is a positive.
Zacks Rank
Currently, Integer Holdings carries a Zacks Rank #3 (Hold).
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks in the broader medical space that have already announced their quarterly results are Thermo Fisher Scientific Inc. (TMO - Free Report) , Align Technology, Inc. (ALGN - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While both Thermo Fisher and AngioDynamics carry aZacks Rank of 2 (Buy), Align Technology sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
AngioDynamics reported first-quarter fiscal 2021 adjusted earnings per share (EPS) of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
Have You Seen Zacks’ 2020 Election Stock Report?
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.
The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Check out Zacks’ 2020 Election Stock Report >>